Search

Your search keyword '"Verzenio (Medication)"' showing total 189 results
Start Over Descriptor "Verzenio (Medication)" Topic jardiance (medication)
189 results on '"Verzenio (Medication)"'

1. Lilly reports full Q4 2024 financial results and provides 2025 guidance

Subjects
Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication), Zepbound (Medication), Diseases, Company sales and earnings, Company earnings/profit, Chronic diseases, Insulin lispro, Semaglutide
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced its financial results for the fourth quarter of 2024 and detailed 2025 [...]

Published
2025

2. Lilly reports Q 3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Subjects
Eli Lilly and Co. -- Company sales and earnings, Company earnings/profit, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. 'Lilly had another strong growth quarter in Q3, with total revenue increasing [...]

Published
2025

3. Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion

Subjects
Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Insulin lispro, Company earnings/profit, Business, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Baqsimi (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in [...]

Published
2024

4. Event Brief of Q4 2023 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Lilly Research Laboratories -- Conferences, meetings and seminars, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Executive VP & CFO . Daniel M. Skovronsky - Eli Lilly and Company,EVP, Chief Scientific Officer and President of Lilly Research [...]

Published
2024

5. Q4 2023 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2023 Earnings Call. (Operator Instructions) I would now like to turn the conference over [...]

Published
2024

6. Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum

Subjects
Eli Lilly and Co., Pharmaceutical industry, Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

ENPNewswire-May 1, 2024--Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 30042024 - INDIANAPOLIS - Eli [...]

Published
2024

7. Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum

Subjects
Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Atopic dermatitis, Sleep apnea syndromes, Company earnings/profit, Business, News, opinion and commentary, Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission [...]

Published
2024

8. Lilly Reports Strong Fourth Quarter 2023 Financial Results and Provides 2024 Guidance

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication), Humalog (Medication), Zepbound (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2023. '2023 was a year of tremendous achievement for Lilly, which delivered life-changing [...]

Published
2024

9. Q3 2023 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2023 Earnings Call. (Operator Instructions) I would now like to turn the conference over [...]

Published
2023

10. Event Brief of Q3 2023 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Lilly Research Laboratories -- Conferences, meetings and seminars, Patient compliance -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Executive VP & CFO . Anne E. White - Eli Lilly and Company,EVP & President of Lilly Neuroscience . Daniel M. [...]

Published
2023

11. Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2023. '2023 was [...]

Published
2024

12. Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

Subjects
Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication)
Abstract

Revenue in Q4 2023 increased 28%. New Products[sup.(i)] revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products[sup.(ii)] revenue increased 9% to [...]

Published
2024

13. Event Brief of Q1 2023 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Lilly Research Laboratories, Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Executive VP & CFO . Anne E. White - Eli Lilly and Company,EVP & President of Lilly Neuroscience . Daniel M. [...]

Published
2023

14. Q1 2023 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2023 Earnings Conference Call. (Operator Instructions). I would now like to turn the conference [...]

Published
2023

15. Event Brief of Q4 2022 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2023

16. Q4 2022 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2022 Earnings Conference Call. (Operator Instructions) And as a reminder, today's conference is being [...]

Published
2023

17. Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, General interest, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2023. 'Lilly had [...]

Published
2023

18. Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH, Eli Lilly and Co., Ulcerative colitis, Viral antibodies, Antibodies, Pharmaceutical industry, Business, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication), Zyprexa (Medication)
Abstract

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding [...]

Published
2023

19. Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum

Subjects
Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Atopic dermatitis, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth [...]

Published
2023

20. Event Brief of Q1 2022 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2022

21. Q1 2022 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2022 Earnings Call. (Operator Instructions) And as a reminder, your conference is being recorded. [...]

Published
2022

22. Event Brief of Q4 2021 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Centers for Medicare and Medicaid Services, Eli Lilly and Co., Pharmaceutical industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2022

23. Q4 2021 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Centers for Medicare and Medicaid Services, Eli Lilly and Co., Pharmaceutical industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2021 Earnings Call. (Operator Instructions) As a reminder, today's conference is being recorded. I [...]

Published
2022

24. Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2022. '2023 is [...]

Published
2023

25. Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth of key growth products, [...]

Published
2023

26. Eli Lilly and Co Investment Community Meeting - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Securities industry, Securities industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

Presentation KEVIN HERN, VP OF IR, ELI LILLY AND COMPANY: Good morning, everyone. Thanks for joining us at Eli Lilly and Company's 2021 Investment Community Meeting. I'm Kevin Hern, the [...]

Published
2021

27. Eli Lilly and Co Investment Community Meeting - Final

Subjects
Eli Lilly and Co., Securities industry, Pharmaceutical industry, Securities industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

Presentation KEVIN HERN, VP OF IR, ELI LILLY AND COMPANY: Good morning, everyone. Thanks for joining us at Eli Lilly and Company's 2021 Investment Community Meeting. I'm Kevin Hern, the [...]

Published
2021

28. Event Brief of Q3 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Semglee (Medication), Emgality (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2021

29. Q3 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Semglee (Medication), Emgality (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by and welcome to the Lilly Quarter 3 2021 Earnings Call. (Operator Instructions) As a reminder, today's conference is being recorded. [...]

Published
2021

30. Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress

Subjects
United States. Food and Drug Administration -- Officials and employees, Boehringer Ingelheim GmbH -- Company sales and earnings -- Officials and employees, Eli Lilly and Co. -- Officials and employees -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings -- Officials and employees, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and [...]

Published
2022

31. Q2 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication), Semglee (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to Lilly's Q2 Earnings Call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now [...]

Published
2021

32. Event Brief of Q2 2021 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Centers for Medicare and Medicaid Services, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication), Semglee (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel [...]

Published
2021

33. Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2022. 'We had [...]

Published
2022

34. Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Mounjaro (Medication), Taltz (Medication)
Abstract

Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than [...]

Published
2022

35. Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%. Outside of revenue from [...]

Published
2022

36. Event Brief of Eli Lilly and Co 2021 Guidance Call - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Executives, Type 2 diabetes, Pharmaceutical industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

CORPORATE PARTICIPANTS . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer & President of Lilly Research Labs . David A. Ricks - Eli Lilly and Company,Chairman, [...]

Published
2020

37. Eli Lilly and Co 2021 Guidance Call - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Chief financial officers, Type 2 diabetes, Pharmaceutical industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly 2021 Guidance Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I [...]

Published
2020

38. Event Brief of Q3 2020 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

CORPORATE PARTICIPANTS . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer [...]

Published
2020

39. Q3 2020 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to Lilly's Q3 2020 Earnings Call. (Operator Instructions) And as a reminder, your conference is being recorded. I [...]

Published
2020

40. Event Brief of Q2 2020 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

CORPORATE PARTICIPANTS . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer [...]

Published
2020

41. Q2 2020 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2020 Earnings Call. (Operator Instructions) As a reminder, today's call is being recorded. I [...]

Published
2020

42. Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. [...]

Published
2022

43. Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

- Revenue in the fourth quarter of 2021 increased 8 percent, driven by volume growth of 11 percent. Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent. - Full-year 2021 [...]

Published
2022

44. Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. 'Lilly demonstrated [...]

Published
2021

45. Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

- Revenue in the third quarter of 2021 increased 18 percent, driven by volume growth of 17 percent. When excluding revenue from COVID-19 therapies, revenue growth was 11 percent in [...]

Published
2021

46. Eli Lilly and Company UK

Subjects
Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Emgality (Medication), Rankings, Management, Company business management, Pharmaceutical industry -- Rankings, Pemetrexed -- Rankings, Medical economics, Baricitinib, Partnerships, Workers
Abstract

Founded by Eli Lilly in 1876, we are one of the largest pharmaceutical companies in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

47. Eli Lilly and Company UK

Subjects
Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Emgality (Medication), Rankings, Management, Company business management, Pharmaceutical industry -- Rankings, Pemetrexed -- Rankings, Medical economics, Baricitinib, Partnerships, Workers
Abstract

Founded by Eli Lilly in 1876, we are one of the largest pharmaceutical companies in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

48. Eli Lilly and Company UK

Subjects
United States. Food and Drug Administration -- Tax policy -- Management, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Emgality (Medication), Rankings, Management, Tax policy, Company business management, Empagliflozin, Type 2 diabetes, Sorafenib -- Rankings, Fulvestrant -- Rankings, Pharmaceutical industry -- Rankings, Dulaglutide, Medical economics, Partnerships, Workers
Abstract

Founded by Eli Lilly in 1876, we are one of the largest pharmaceutical companies in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

49. Eli Lilly and Company UK

Subjects
United States. Food and Drug Administration -- Tax policy -- Management, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Emgality (Medication), Rankings, Management, Tax policy, Company business management, Empagliflozin, Type 2 diabetes, Sorafenib -- Rankings, Fulvestrant -- Rankings, Pharmaceutical industry -- Rankings, Dulaglutide, Medical economics, Partnerships, Workers
Abstract

Founded by Eli Lilly in 1876, we are one of the largest pharmaceutical companies in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

50. Eli Lilly and Company UK

Subjects
United States. Food and Drug Administration -- Tax policy -- Management, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Emgality (Medication), Rankings, Management, Tax policy, Company business management, Empagliflozin, Type 2 diabetes, Sorafenib -- Rankings, Fulvestrant -- Rankings, Pharmaceutical industry -- Rankings, Dulaglutide, Medical economics, Partnerships, Workers
Abstract

Founded by Eli Lilly in 1876, we are one of the largest pharmaceutical companies in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results